ASP Isotopes ($ASPI) Investor Settlement

ASP Isotopes has reached a tentative settlement to resolve investor claims that it overstated the readiness of its enrichment technology for uranium and HALEU production.

Outline:

On September 26, 2024, ASPI promoted its enrichment technology as a strong solution for uranium and HALEU production. On October 17 and October 30, 2024, it announced progress in quantum enrichment and a TerraPower term sheet, sending $ASPI higher. Investors later said the company had never actually tested its process on uranium, even as it raised $18.6 million in a November 2024 stock sale. After a November 26, 2024 research report and Mann’s November 27, 2024 interview, the matter moved to a tentative settlement.

Timeline:

• September 26, 2024: ASPI published an investor presentation and conference-call remarks promoting quantum enrichment as a strong solution for uranium and HALEU production.

• October 17, 2024: ASPI said it had enriched Ytterbium-176 during commissioning of its first quantum enrichment facility and suggested the process could support HALEU production.

• October 30, 2024: ASPI announced a term sheet with TerraPower tied to construction of a HALEU production facility and a future 10-year supply arrangement. $ASPI closed up 19.8%.

• November 4, 2024: ASPI completed a public stock offering of 2,754,250 shares.

• November 19, 2024: POWER magazine published comments from ASPI saying its technology was prepared for deployment and that it was targeting a uranium enrichment facility once permits were obtained.

• November 26, 2024: Fuzzy Panda Research published a report challenging ASPI’s uranium enrichment claims, and $ASPI fell 23.5%.

• November 27, 2024: In a Canaccord interview, Mann said ASPI had not actually enriched uranium, and $ASPI fell another 14.2%.

• April 2026: The parties decide to settle the lawsuit

Background:

ASP Isotopes is a small South Africa-based isotope enrichment company whose business was built around assets, intellectual property, and personnel taken over from Klydon. It generated little revenue, posted heavy losses, and depended on investor funding to keep operating and build its facilities.

In 2024, ASPI made uranium and HALEU a central part of its story. It told the market its quantum enrichment technology was well suited for uranium, presented comparison data against other enrichment methods, and said its team had used lasers to enrich uranium.

The company then highlighted milestones that appeared to support that strategy. On October 17, 2024, it announced successful enrichment of Ytterbium-176 at its first quantum enrichment facility and said the same platform could support HALEU. On October 30, 2024, it announced a term sheet with TerraPower tied to a future HALEU facility and long-term supply, and soon after sold $18.6 million of stock.

Investors say those statements left out a basic problem: neither ASPI nor predecessor Klydon had ever actually worked with or tested the technology on uranium. That issue came into sharper focus after the November 26, 2024 Fuzzy Panda report and a November 27, 2024 interview in which Mann said ASPI had not actually enriched uranium and still needed to test the process on it.

Those disclosures sent the stock sharply lower over two days. The matter has now moved to a tentative settlement, though the source provided does not state the amount or next dates.

What Can Investors Expect Now?

ASP Isotopes has reached a tentative settlement to resolve investor claims that it overstated the readiness of its enrichment technology for uranium and HALEU production.

If you were damaged due to this situation, you can file for a payout and get your share of the settlement. You can check if you are eligible and other details in the FAQ section